Sexual Life in Gynecological Cancer Patients
Özet
Gynecological cancers are common among women. The diagnosis and treatment process can lead to various negative impacts on physical, psychological, and sexual well-being. Moreover, cultural factors, partner relationships, and the stage of the disease play significant roles in sexual life. Therefore, developing patient-centered and individualized approaches is crucial for improving both treatment outcomes and overall quality of life. Treatments such as surgery, chemotherapy, and radiotherapy can cause sexual dysfunctions like vaginal dryness, dyspareunia, loss of libido, and body image disturbances. Sexual dysfunction is diagnosed according to the DSM-5 criteria, and its treatment typically involves lifestyle changes, pelvic floor exercises, moisturizers, hormonal and non-hormonal therapies, and psychological support. New treatment options, such as ospemifene, show promise. Providing counseling at an early stage and ensuring that healthcare professionals receive training on this subject will positively contribute to patients’ rehabilitation process. Sexual dysfunction should be addressed concurrently during the diagnostic and treatment process, with healthcare professionals encouraging patients to discuss this issue. Sexual health is an integral part of quality of life and should be supported through a multidisciplinary approach.
Referanslar
Northwestern Medicine. Gynecologic Cancer [Internet]. [cited 2025 Jul 27].
World Cancer Research Fund. Worldwide cancer data [Internet]. [cited 2025 Jul 27].
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2023. CA Cancer J Clin. 2023;73(1):17–48.
Brotto LA, Yule M, Breckon E. Psychological interventions for the sexual sequelae of cancer: a review of the literature. J Cancer Surviv. 2010;4(4):346–60.
Cancer.net. Addressing common sexual health concerns during cancer survivorship [Internet]. [cited 2025 Jul 25].
Centers for Disease Control and Prevention. Gynecologic Cancers [Internet]. 2017 [cited 2025 Jul 25].
Abbott-Anderson K, Kwekkeboom KL. A systematic review of sexual concerns reported by gynecological cancer survivors. Gynecol Oncol. 2012;124(3):477–89.
Smith T, Kingsberg SA, Faubion S. Sexual dysfunction in female cancer survivors: Addressing the problems and the remedies. Maturitas. 2022;165:52–7.
Guntupalli SR, Sheeder J, Ioffe Y, et al. Sexual and marital dysfunction in women with gynecologic cancer. Int J Gynecol Cancer. 2017;27(3):603–7.
Lin H, Fu HC, Wu CH, et al. Evaluation of sexual dysfunction in gynecologic cancer survivors using DSM-5 diagnostic criteria. BMC Womens Health. 2022;22(1):1.
Jackson KS, Naik R. Pelvic floor dysfunction and radical hysterectomy. Int J Gynecol Cancer. 2006;16(1):354–63.
Serati M, Salvatore S, Uccella S, et al. Sexual function after radical hysterectomy for early-stage cervical cancer: Is there a difference between laparoscopy and laparotomy? J Sex Med. 2009;6:2516–22.
Corrêa CSL, Leite ICG, Andrade APS, et al. Sexual function of women surviving cervical cancer. Arch Gynecol Obstet. 2015;293:1053–63.
Domenici L, Palaia I, Giorgini M, et al. Sexual health and quality of life assessment among ovarian cancer patients during chemotherapy. Oncology. 2016;91(4):205–10.
Vaz AF, Pinto-Neto AM, Conde DM, et al. Quality of life and menopausal and sexual symptoms in gynecologic cancer survivors: a cohort study. Menopause. 2011;18(6):662–9.
World Health Organization. Sexual health [Internet]. [cited 2025 Jul 28].
American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 5th ed. Arlington (VA): American Psychiatric Publishing; 2013.
Del Pup L, Villa P, Amar ID, et al. Approach to sexual dysfunction in women with cancer. Int J Gynecol Cancer. 2019;29(3):630–4.
Cardoso F, Loibl S, Pagani O. The European Society of Breast Cancer specialists recommendations for the management of young women with breast cancer. Eur J Cancer. 2012;48:3355–77.
Luo F, Link M, Grabenhorst C, et al. Low sexual desire in breast cancer survivors and patients: A review. Sex Med Rev. 2022;10:367–75.
Kingsberg SA, Althof S, Simon JA, et al. Female sexual dysfunction—Medical and psychological treatments. J Sex Med. 2017;14:1463–91.
Mac Bride MB, Rhodes DJ, Shuster LT. Vulvovaginal atrophy. Mayo Clin Proc. 2010;85:87–94.
Barcellini A, Dominoni M, Dal Mas F, et al. Sexual health dysfunction after radiotherapy for gynecological cancer: Role of physical rehabilitation including pelvic floor muscle training. Front Med (Lausanne). 2021;8:813352.
Nappi RE, Palacios S. Impact of vulvovaginal atrophy on sexual health and quality of life at postmenopause. Climacteric. 2014;17:3–9.
Sousa MS, Peate M, Jarvis S. A clinical guide to the management of genitourinary symptoms in breast cancer survivors on endocrine therapy. Ther Adv Med Oncol. 2017;9:269–85.
Candy B, Jones L, Vickerstaff V, et al. Interventions for sexual dysfunction following treatments for cancer in women. Cochrane Database Syst Rev. 2016;2(2):CD005540.
U.S. Food and Drug Administration. FDA approves new treatment for hypoactive sexual desire disorder in premenopausal women [Internet]. [cited 2025 Jul 28].
Edinoff AN, Sanders NM, Lewis KB, et al. Bremelanotide for treatment of female hypoactive sexual desire. Neurol Int. 2022;14:75–88.
Parish SJ, Hahn SR. Hypoactive sexual desire disorder: A review of epidemiology, biopsychology, diagnosis, and treatment. Sex Med Rev. 2016;4(2):103–20.
Dhillon S, Keam SJ. Bremelanotide: First approval. Drugs. 2019;79(14):1599–606.
Palacios S, Mejía A, Neyro JL. Treatment of the genitourinary syndrome of menopause. Climacteric. 2015;18(Suppl 1):23–9.
Fallacara A, Baldini E, Manfredini S, Vertuani S. Hyaluronic acid in the third millennium. Polymers (Basel). 2018;10:701.
Harten IA, Evanko SP, Choe CH, et al. The extracellular matrix molecules versican and hyaluronan in urethral and vaginal tissues in stress urinary incontinence. Neurourol Urodyn. 2021;40:771–82.
Faubion SS, Larkin LC, Stuenkel CA, et al. Management of genitourinary syndrome of menopause in women with or at high risk for breast cancer. Menopause. 2018;25:596–608.
Suckling J, Lethaby A, Kennedy R. Local oestrogen for vaginal atrophy in postmenopausal women. Cochrane Database Syst Rev. 2006;(4):CD001500.
Del Pup L, Postruznik D, Corona G. Effect of one-month treatment with vaginal promestriene on serum estrone sulfate levels in cancer patients: a pilot study. Maturitas. 2012;72(1):93–4.
Nappi RE, Murina F, Perrone G, et al. Clinical profile of women with vulvar and vaginal atrophy who are not candidates for local vaginal estrogen therapy. Minerva Ginecol. 2017;69(4):370–80.
Archer DF, Goldstein SR, Simon JA, et al. Efficacy and safety of ospemifene in postmenopausal women with moderate-to-severe vaginal dryness: a phase 3, randomized, double-blind, placebo-controlled, multicenter trial. Menopause. 2019;26:611–21.
Del Pup L. Ospemifene: a safe treatment of vaginal atrophy. Eur Rev Med Pharmacol Sci. 2016;20(18):3934–44.
De Rosa N, Lavitola G, Giampaolino P, et al. Impact of ospemifene on quality of life and sexual function in young survivors of cervical cancer: A prospective study. Biomed Res Int. 2017;2017:7513610.
Goetsch MF, Lim JY, Caughey AB. A practical solution for dyspareunia in breast cancer survivors: a randomized controlled trial. J Clin Oncol. 2015;33(30):3394–400.
